Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse

NCT03229382 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
1
Enrollment
NETWORK
Sponsor class

Stopped Very slow recruitment due to lack of relapse in the observed group of patients

Conditions

Interventions

Sponsor

Polish Lymphoma Research Group

Collaborators